SCHEMBL2486010

SCHEMBL2486010

NCC(N)C(O)CCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 2/20 0.49
ERAP1 Q9NZ08 2/20 0.49
ERAP2 Q6P179 1/20 0.49
METAP2 P50579 2/20 0.46
METAP1 P53582 2/20 0.46
CSNK1E P49674 1/20 0.46
HTR2A P28223 2/20 0.45
CYP2A6 P11509 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TAAR1 Q96RJ0 1/20 0.45
LOXL2 Q9Y4K0 1/20 0.45
MAOA P21397 3/20 0.42
MAOB P27338 3/20 0.42
TDP1 Q9NUW8 1/20 0.40
ACP3 P15309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6891198 0.83 ANPEP (0.47) ANPEPERAP1ERAP2METAP2METAP1
SCHEMBL27630320 0.83 CSNK1E (0.53) ANPEPERAP1ERAP2METAP2METAP1
SCHEMBL8761563 0.82 ANPEP (0.53) ANPEPERAP1ERAP2METAP2METAP1
SCHEMBL30146557 0.81 TDP1 (0.52) ANPEPERAP1ERAP2HTR2ACYP2A6
SCHEMBL30146580 0.81 TDP1 (0.52) ANPEPERAP1ERAP2HTR2ACYP2A6
SCHEMBL7268763 0.81 TDP1 (0.52) ANPEPERAP1ERAP2HTR2ACYP2A6
SCHEMBL8270986 0.80 ERAP1 (0.47) ANPEPERAP1ERAP2METAP2METAP1
SCHEMBL3506697 0.80 ERAP1 (0.47) ANPEPERAP1ERAP2METAP2METAP1
SCHEMBL8884009 0.80 CSNK1E (0.46) ANPEPERAP1ERAP2METAP2METAP1
SCHEMBL296417 0.80 EPHX1 (0.52) ANPEPCSNK1ECYP2A6TAAR1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1017358-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2004-08-11 EP claimed
EP-1017358-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-07-12 EP claimed
US-5939458-A APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN GILLETTE COMPANY, THE 1999-08-17 US claimed
WO-1999015136-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 1999-04-01 WO claimed
CN-107106533-B Synergistic composition for treating microbial infections 罗切斯特大学 2020-11-06 CN disclosed
EP-3212183-B1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIV ROCHESTER (US) 2019-10-02 EP disclosed
US-10028931-B2 Synergistic compositions for treating microbial infections UNIVERSITY OF ROCHESTER (US) 2018-07-24 US disclosed
EP-3212183-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS University of Rochester (US) 2017-09-06 EP disclosed
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIVERSITY OF ROCHESTER (US) 2017-08-31 US disclosed
WO-2016070021-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIVERSITY OF ROCHESTER (US) 2016-05-06 WO disclosed
CN-102348807-B Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system SUTRO BIOPHARMA INC 2015-04-15 CN disclosed
US-8778631-B2 Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system SUTRO BIOPHARMA, INC. (US) 2014-07-15 US disclosed
US-20100184134-A1 DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD SUTRO BIOPHARMA, INC. (US) 2010-07-22 US disclosed
US-20100184135-A1 MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM SUTRO BIOPHARMA, INC. (US) 2010-07-22 US disclosed
WO-2010081110-A1 DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD SUTRO BIOPHARMA, INC. (US) 2010-07-15 WO disclosed
WO-2010081111-A1 MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM SUTRO BIOPHARMA, INC. (US) 2010-07-15 WO disclosed
EP-1017358-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2004-08-11 EP disclosed
EP-1017358-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-07-12 EP disclosed
US-5939458-A APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN GILLETTE COMPANY, THE 1999-08-17 US disclosed
WO-1999015136-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 1999-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028931-B2 Synergistic compositions for treating microbial infections RNASE1, RNASEL, RNASEH1 ANPEP 184/4885ERAP1 65/4885ERAP2 137/4885
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS RNASE1, RNASEL, RNASEH1 ANPEP 184/4885ERAP1 65/4885ERAP2 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.